Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by

Letter to global governments: A call for bold life sciences investment

Letter to global governments: A call for bold life sciences investment
angilma1

/by

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis

  • New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
  • Purpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sites
/by

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis

  • New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
  • Purpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sites
/by